HAMP and myelodysplastic syndrome: The analysis of the included cohort studies yielded the following key findings: (1) serum hepcidin levels were increased by chelation treatment in MDS patients [24,27]; (2) high serum hepcidin levels characterized high-risk MDS [27] and were associated with worse survival in MDS patients.